Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering
Retrieved on:
Monday, September 21, 2020
Oncology, Health, Surgery, Genetics, Research, Science, Biotechnology, Medical specialties, Clinical medicine, Medicine, Animal testing, Molecular biology, Organ transplantation, Life extension, Xenotransplantation, Endogenous retrovirus, Perv, Allotransplantation, Domestic pig, Qihan Biotech, Qihan’s High-Throughput, Multiplexable Genome Editing Platform, Qihan’s Immune Privileged Technology Platform
The results, which were published today in Nature Biomedical Engineering, show enhanced immunocompatibility of xenogeneic organs and full eradication of porcine endogenous retroviruses (PERV).
Key Points:
- The results, which were published today in Nature Biomedical Engineering, show enhanced immunocompatibility of xenogeneic organs and full eradication of porcine endogenous retroviruses (PERV).
- Qihan Biotech is committed to developing novel cell and organ therapies which can be available to patients worldwide.
- Currently, the clinical applicability of allogeneic cell therapies and organ xenotransplantation is limited by molecular incompatibilities between the transplant and the recipient.
- Qihan is also a pioneer in engineering extensively genome-modified pigs as bioreactors to grow xenogeneic cells, tissues and organs for safe and effective clinical applications.